Company intelligence / Profile preview

Kanghong Biological

Chengdu, Sichuan, Chinaen.cnkh.com ↗

Ownership: Private
Employees: ~4000
Development stage: Other

Overview

Kanghong Pharmaceutical's conbercept (Lumitin), an anti-VEGF therapy for ophthalmic diseases, is commercially approved in China and in Phase III development in the US. The company has gene therapy candidates in Phase I trials in both China and the US for age-related macular degeneration and other retinal diseases. Monoclonal antibody programs are in Phase I for neoplasms and autoimmune diseases[1][2][5].

Therapeutic areas: OncologyDermatologyOphthalmologyNeurologyEndocrinologyGastroenterology
Modalities: Monoclonal antibodyGene therapySmall moleculeBiological products
Industry: Biotech

Partnerships

BioLight Israeli Life Sciences Investment (through IOPtima)Distribution partnerships for international expansion

Beyond the preview

Go deeper on Kanghong Biological.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kanghong Biological.

Explore the full profile